Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A new drug strategy improves hair loss treatment with better results and safety.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

The formulated gel is a promising treatment for alopecia areata.

New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Allethrin caused harmful effects and organ damage in rats, worsening with higher doses and longer exposure.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Early diagnosis and combination therapy, especially with finasteride and dutasteride, are key to managing Frontal Fibrosing Alopecia effectively.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Reducing PEDF may help treat hair loss.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

14,15-EET may help reduce poststroke pain by affecting certain brain proteins.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Different enzymes are active in different parts of developing mouse organs.

The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.

CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Frontal Fibrosing Alopecia mainly affects postmenopausal women and is linked to thyroid disease, hyperlipidemia, and anemia.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

Araliadiol may promote hair growth like minoxidil without being toxic.

Different types of androgens bind differently to two receptors, AR1 and AR2, in Atlantic croaker's brain and ovarian tissues, suggesting these receptors may control different androgen actions in fish.

The new minoxidil formulation could better promote hair growth for treating androgenic alopecia.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.